US research roundup: Eli Lilly, General Dynamics, S&P Global
LLY•Analysts raised Eli Lilly’s price target to $1,570 from $1,400, General Dynamics’ to $455 from $440 and S&P Global’s to $572 from $553. Targets were also raised for AbbVie and CBOE Global Markets.
1. Selected target changes
Berenberg raised its Eli Lilly target price to $1,570 from $1,400. Jefferies raised its General Dynamics target to $455 from $440, and Barclays raised its S&P Global target to $572 from $553. Morgan Stanley lifted its CBOE Global Markets target to $461 from $450; multiple analysts also raised targets for AbbVie.
